333 related articles for article (PubMed ID: 16832836)
1. p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate.
Kunisaki R; Ikawa S; Maeda T; Nakazaki Y; Kurita R; Harata M; Shutoh Y; Bai YS; Soda Y; Tanabe T; Dohi T; Kato R; Ikawa Y; Asano S; Tani K
J Gene Med; 2006 Sep; 8(9):1121-30. PubMed ID: 16832836
[TBL] [Abstract][Full Text] [Related]
2. Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters.
Kato S; Shimada A; Osada M; Ikawa S; Obinata M; Nakagawara A; Kanamaru R; Ishioka C
Cancer Res; 1999 Dec; 59(23):5908-11. PubMed ID: 10606233
[TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers.
Hagiwara K; McMenamin MG; Miura K; Harris CC
Cancer Res; 1999 Sep; 59(17):4165-9. PubMed ID: 10485447
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin-controlled p53 gene therapy for human non-small cell lung cancer xenografts in athymic nude mice via the CArG elements.
Wang WD; Li R; Chen ZT; Li DZ; Duan YZ; Cao ZH
Cancer Sci; 2005 Oct; 96(10):706-12. PubMed ID: 16232203
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non-small cell lung cancer and breast cancer.
Sunahara M; Shishikura T; Takahashi M; Todo S; Yamamoto N; Kimura H; Kato S; Ishioka C; Ikawa S; Ikawa Y; Nakagawara A
Oncogene; 1999 Jun; 18(25):3761-5. PubMed ID: 10391684
[TBL] [Abstract][Full Text] [Related]
6. The p53-independent tumoricidal activity of an adenoviral vector encoding a p27-p16 fusion tumor suppressor gene.
Patel SD; Tran AC; Ge Y; Moskalenko M; Tsui L; Banik G; Tom W; Scott M; Chen L; Van Roey M; Rivkin M; Mendez M; Gyuris J; McArthur JG
Mol Ther; 2000 Aug; 2(2):161-9. PubMed ID: 10947944
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated transfer of the p53 family genes, p73 and p51/p63 induces cell cycle arrest and apoptosis in colorectal cancer cell lines: potential application to gene therapy of colorectal cancer.
Sasaki Y; Morimoto I; Ishida S; Yamashita T; Imai K; Tokino T
Gene Ther; 2001 Sep; 8(18):1401-8. PubMed ID: 11571580
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Horowitz J
Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
[TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53.
Pataer A; Fanale MA; Roth JA; Swisher SG; Hunt KK
Cancer Gene Ther; 2006 Aug; 13(8):806-14. PubMed ID: 16628227
[TBL] [Abstract][Full Text] [Related]
10. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer.
Spitz FR; Nguyen D; Skibber JM; Cusack J; Roth JA; Cristiano RJ
Anticancer Res; 1996; 16(6B):3415-22. PubMed ID: 9042200
[TBL] [Abstract][Full Text] [Related]
11. The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer.
Rizk NP; Chang MY; El Kouri C; Seth P; Kaiser LR; Albelda SM; Amin KM
Cancer Gene Ther; 1999; 6(4):291-301. PubMed ID: 10419047
[TBL] [Abstract][Full Text] [Related]
12. Tumor growth suppression by adenovirus-mediated introduction of a cell-growth-suppressing gene tob in a pancreatic cancer model.
Yanagie H; Tanabe T; Sumimoto H; Sugiyama H; Matsuda S; Nonaka Y; Ogiwara N; Sasaki K; Tani K; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 May; 63(4):275-86. PubMed ID: 18657378
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo.
Ghaneh P; Greenhalf W; Humphreys M; Wilson D; Zumstein L; Lemoine NR; Neoptolemos JP
Gene Ther; 2001 Feb; 8(3):199-208. PubMed ID: 11313791
[TBL] [Abstract][Full Text] [Related]
14. [Effects of exogenous wild type p53 on malignant growth of human lung cancer cell line].
Wang H; Lai B; Li J
Zhonghua Jie He He Hu Xi Za Zhi; 1998 May; 21(5):268-72. PubMed ID: 11326947
[TBL] [Abstract][Full Text] [Related]
15. Viral and non-viral vectors for cancer gene therapy.
Cristiano RJ
Anticancer Res; 1998; 18(5A):3241-5. PubMed ID: 9858889
[TBL] [Abstract][Full Text] [Related]
16. Restoration of p53 function in anaplastic Wilms' tumor.
Delatte SJ; Hazen-Martin DJ; Re GG; Kelly JR; Sutphin A; Tagge EP
J Pediatr Surg; 2001 Jan; 36(1):43-50. PubMed ID: 11150436
[TBL] [Abstract][Full Text] [Related]
17. Suppression of tumor growth using a recombinant adenoviral vector carrying the dominant-negative mutant gene Survivin-D53A in a nude mice model.
Zhu DE; Höti N; Song Z; Jin L; Wu Z; Wu Q; Wu M
Cancer Gene Ther; 2006 Aug; 13(8):762-70. PubMed ID: 16543917
[TBL] [Abstract][Full Text] [Related]
18. [Adenovirus-mediated p53 gene therapy of human laryngeal cancer].
Wang Q; Han D; Wang W
Zhonghua Zhong Liu Za Zhi; 1998 Nov; 20(6):418-21. PubMed ID: 10920932
[TBL] [Abstract][Full Text] [Related]
19. Adenoviral-mediated gene transfer of Gadd45a results in suppression by inducing apoptosis and cell cycle arrest in pancreatic cancer cell.
Li Y; Qian H; Li X; Wang H; Yu J; Liu Y; Zhang X; Liang X; Fu M; Zhan Q; Lin C
J Gene Med; 2009 Jan; 11(1):3-13. PubMed ID: 19003803
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer.
Modesitt SC; Ramirez P; Zu Z; Bodurka-Bevers D; Gershenson D; Wolf JK
Clin Cancer Res; 2001 Jun; 7(6):1765-72. PubMed ID: 11410518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
